ATXI (Avenue Therapeutics) Insider Ownership : 4.21 % (As of Dec. 15, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Avenue Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Avenue Therapeutics's insider ownership is 4.21%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Avenue Therapeutics's Institutional Ownership is 12.31%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Avenue Therapeutics's Float Percentage Of Total Shares Outstanding is 93.25%.

Avenue Therapeutics Insider Ownership Historical Data

The historical data trend for Avenue Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenue Therapeutics Insider Ownership Chart

Avenue Therapeutics Historical Data

The historical data trend for Avenue Therapeutics can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Insider Ownership	20.15	20.15	19.50	20.81	20.81	14.08	14.08	5.00	5.00	4.21

Avenue Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Avenue Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (NAS:ATXI) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

49Y:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154

Website

https://www.avenuetx.com

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

Executives

Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Jay D Kranzler	director	4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Invagen Pharmaceuticals, Inc.	10 percent owner	SITE B, 7 OSER AVE., HAUPPAUGE NY 11788
Alexandra Maclean	officer: Chief Executive Officer	C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
David Jin	officer: Int. PEO, Int. PFO, and COO	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Joseph Walter Vazzano	officer: Chief Financial Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Curtis Gale Oltmans	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301
Lucy Lu	director, officer: President, CEO	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elizabeth Garrett Ingram	director	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Thomas Gregory Moore	director	C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045
Nishant Saxena	director	CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013
Jaideep Ashok Gogtay	director	CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008